| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TARS | Common Stock | Options Exercise | +2,653 | +239% | 3,764 | 15 Mar 2023 | Direct | F1, F2 | ||
| transaction | TARS | Common Stock | Sale | $2,511 | -187 | -5% | $13.43 | 3,577 | 16 Mar 2023 | Direct | F3 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | TARS | Restricted Stock Units | Options Exercise | $0 | -2,653 | -25% | $0.000000 | 7,959 | 15 Mar 2023 | Common Stock | 2,653 | Direct | F4, F5 |
| Id | Content |
|---|---|
| F1 | The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). |
| F2 | Includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022. |
| F3 | The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| F4 | Each RSU represents a contingent right to receive one share of the Company's common stock. |
| F5 | RSU granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2023, 2024, 2025, and 2026, subject to the Reporting Person's continuous service. |